Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea Pharmaceutica (SIX: BSLN) records first commercial milestone payment from Japan
Published by Jyoti Prakash, CFA

Basilea Pharmaceutica has announced the receipt of its first commercial milestone payment of CHF1.2m from partner Asahi Kasei Pharma (AKP) for reaching an undisclosed sales threshold in Japan for its lead anti-infective drug Cresemba. Japan, along with China, are key new markets for Cresemba, making up c 25% of the drug’s global potential.  Cresemba recorded global in-market sales of US$533m in the 12-month period ending September 2024, at a 20% y-o-y growth rate. Importantly, unlike the US and European markets, where Cresemba is approaching maturity (market protection up to Q427), Japan is a fairly new entry for Cresemba (launched in January 2024, triggering a CHF5m development milestone from AKP), which comes with significantly longer exclusivity period and should support lifecycle management.

Latest

Industrials | Comment

Earnz (AIM: EARN) – Proposed acquisition of Zero Carbon Group

Industrials | Comment

Electro Optic Systems (ASX: EOS) announces US$45m order win

Financials | Comment

Revolut secures full UK banking licence

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) confirms new CEO